One of the largest clinical trials done in infants with congenital heart diseases shows that the increasingly common practice of using the drug clopidogrel (Plavix) to reduce shunt-related blood flow issues is not effective in the dose studied.
One of the largest clinical trials done in infants with congenital heart diseases shows that the increasingly common practice of using the drug clopidogrel (Plavix) to reduce shunt-related blood flow issues is not effective in the dose studied.